Apollomics, Inc. (NASDAQ:APLM – Get Free Report) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totalling 3,300 shares, a drop of 19.5% from the August 31st total of 4,100 shares. Based on an average daily volume of 17,400 shares, the short-interest ratio is currently 0.2 days. Approximately 0.1% of the company’s stock are sold short.
Apollomics Stock Down 5.1 %
Shares of NASDAQ APLM opened at $3.74 on Monday. Apollomics has a fifty-two week low of $3.48 and a fifty-two week high of $49.00. The firm’s 50 day simple moving average is $4.66.
Institutional Investors Weigh In On Apollomics
Institutional investors and hedge funds have recently made changes to their positions in the company. George Kaiser Family Foundation bought a new stake in Apollomics in the 1st quarter worth approximately $16,238,000. Clear Street LLC purchased a new stake in Apollomics in the 1st quarter worth $165,000. Geode Capital Management LLC bought a new stake in shares of Apollomics in the 1st quarter worth about $325,000. Exchange Traded Concepts LLC purchased a new stake in shares of Apollomics during the 2nd quarter valued at about $166,000. Finally, Levin Capital Strategies L.P. purchased a new stake in Apollomics in the 2nd quarter worth about $62,000. Institutional investors own 1.62% of the company’s stock.
About Apollomics
Apollomics, Inc, a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain.
Read More
- Five stocks we like better than Apollomics
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Will the Energy Sector Continue to Outshine the Market?
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- MarketBeat Week in Review – 9/25 – 9/29
- How to Invest in Cannabis, Step by Step
- CarMax Slides On Earnings Disappointment, Time To Celebrate?
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
